|
|
|
|
|
|
Sponsors and Collaborators: |
Louisiana State University - Shreveport SAM Technology & The San Francisco Brain Research Institute |
Information provided by: | Louisiana State University - Shreveport |
ClinicalTrials.gov Identifier: | NCT00211380 |
This is the sister study to the BMS "Cognitive Improvement with Aripiprazole (Abilify)" study (LSUHSC #H04-022). Evaluation of cognitive ability in patients with schizophrenia or schizoaffective disorder both before and after a switch from risperidone, olanzapine, or risperidone Consta injections to aripiprazole may reveal some of the cognitive changes that correlate with the improved response, better side effect profile, and effects on other components of the negative symptom array. Further, examination of brain functional activity using functional magnetic resonance imaging (fMRI) during an episodic memory task, as well as behavioral performance and associated electroencephalographic (EEG) data of working memory and intermediate term verbal memory collected with the Sustained Attention and Memory Brain Function Test (SAM-BFT), may also provide data showing the neural correlates of these changes in cognition.
Condition | Intervention |
Schizophrenia Schizoaffective Disorder |
Drug: aripiprazole |
MedlinePlus related topics: | Memory Schizophrenia |
ChemIDplus related topics: | Aripiprazole |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia, (SFBRI). |
Enrollment: | 8 |
Study Start Date: | August 2003 |
Study Completion Date: | February 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Patients (n=10):
Controls (n=10):
Exclusion Criteria:
Patients:
Controls:
Dropout criteria: subjects that begin the study and are not able to finish the study will be tracked. Ongoing criteria for termination from the study will include:
United States, Louisiana | |||||
Psychopharmacology Research Clinic | |||||
Shreveport, Louisiana, United States, 71103 |
Louisiana State University - Shreveport |
SAM Technology & The San Francisco Brain Research Institute |
Principal Investigator: | James C Patterson, MD, PhD | LSU Health Sciences Center-Shreveport/Department of Psychiatry |
Responsible Party: | LSU Health Sciences Center ( James C. Patterson, II, MD, PhD ) |
Study ID Numbers: | LSUHSC #H04-021 |
First Received: | September 13, 2005 |
Last Updated: | February 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00211380 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|